AU781950B2 - Immunomodulating polymers - Google Patents

Immunomodulating polymers Download PDF

Info

Publication number
AU781950B2
AU781950B2 AU40563/00A AU4056300A AU781950B2 AU 781950 B2 AU781950 B2 AU 781950B2 AU 40563/00 A AU40563/00 A AU 40563/00A AU 4056300 A AU4056300 A AU 4056300A AU 781950 B2 AU781950 B2 AU 781950B2
Authority
AU
Australia
Prior art keywords
polymer
repeating
positively charged
repeating charge
free amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU40563/00A
Other languages
English (en)
Other versions
AU4056300A (en
Inventor
Dennis L Kasper
Andrew B Onderdonk
Arthur O. Tzianabos
Ying Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Publication of AU4056300A publication Critical patent/AU4056300A/en
Priority to AU2005201963A priority Critical patent/AU2005201963B2/en
Application granted granted Critical
Publication of AU781950B2 publication Critical patent/AU781950B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU40563/00A 1999-04-02 2000-03-31 Immunomodulating polymers Ceased AU781950B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2005201963A AU2005201963B2 (en) 1999-04-02 2005-05-10 Immunomodulating polymers

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12758499P 1999-04-02 1999-04-02
US60/127584 1999-04-02
US16245799P 1999-10-29 1999-10-29
US60/162457 1999-10-29
PCT/US2000/008586 WO2000059515A2 (fr) 1999-04-02 2000-03-31 Polymeres immunoregulateurs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2005201963A Division AU2005201963B2 (en) 1999-04-02 2005-05-10 Immunomodulating polymers

Publications (2)

Publication Number Publication Date
AU4056300A AU4056300A (en) 2000-10-23
AU781950B2 true AU781950B2 (en) 2005-06-23

Family

ID=26825761

Family Applications (1)

Application Number Title Priority Date Filing Date
AU40563/00A Ceased AU781950B2 (en) 1999-04-02 2000-03-31 Immunomodulating polymers

Country Status (8)

Country Link
EP (1) EP1169045A2 (fr)
JP (2) JP2002541113A (fr)
CN (1) CN1362880A (fr)
AU (1) AU781950B2 (fr)
BR (1) BR0009531A (fr)
CA (1) CA2366895A1 (fr)
MX (1) MXPA01009930A (fr)
WO (1) WO2000059515A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SV2003000753A (es) 2000-12-05 2003-06-16 Brigham & Womens Hospital Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
WO2003066053A1 (fr) * 2002-02-07 2003-08-14 Rutgers, The State University Polymeres antibiotiques
EP1494687A2 (fr) * 2002-03-08 2005-01-12 Eli Lilly And Company Antigenes polymeres immunomodulateurs pour le traitement de maladies inflammatoires
EP1638581A2 (fr) * 2003-03-31 2006-03-29 The Brigham And Women's Hospital, Inc. Immunomodulateurs zwitterioniques destines au traitement de l'asthme et des allergies
WO2007092451A2 (fr) 2006-02-06 2007-08-16 The Brigham And Women's Hospital, Inc. Polysaccharides zwitterioniques pour favoriser la maturation du système immunitaire et la santé
EP2217250A4 (fr) * 2007-11-09 2011-01-05 California Inst Of Techn Composés immunorégulateurs et compositions et procédés apparentés
US8580278B2 (en) 2009-06-03 2013-11-12 Trustees Of Dartmouth College Nutraceutical composition and methods for preventing or treating multiple sclerosis
EP2555753B1 (fr) 2010-04-07 2018-08-01 California Institute of Technology Véhicule destiné à distribuer un composé à une muqueuse et compositions, procédés et systèmes apparentés
US9539281B2 (en) 2011-07-12 2017-01-10 The Brigham And Women's Hospital, Inc. Lipid-containing PSA compositions, methods of isolation and methods of use thereof
EP2994161B1 (fr) 2013-05-10 2020-10-28 California Institute of Technology Prévention et traitement probiotiques du cancer du côlon
JP6206916B2 (ja) * 2013-11-15 2017-10-04 国立研究開発法人物質・材料研究機構 細胞間情報伝達分子産生信号誘発機能高分子及びその合成方法
US11331335B2 (en) 2015-06-10 2022-05-17 California Institute Of Technology Sepsis treatment and related compositions methods and systems
CN108135167B (zh) 2015-08-19 2021-07-09 哈佛学院院长及董事 脂化psa组合物和方法
WO2018014012A1 (fr) 2016-07-15 2018-01-18 President And Fellows Of Harvard College Compositions de glycolipide et procédés d'utilisation
JP6790260B2 (ja) 2016-10-27 2020-11-25 チャン グァン メモリアル ホスピタル，リンコウＣｈａｎｇ Ｇｕｎｇ Ｍｅｍｏｒｉａｌ Ｈｏｓｐｉｔａｌ，Ｌｉｎｋｏｕ スルファメトキサゾールおよび／またはトリメトプリムによって誘発される薬物アレルギー反応のリスクを評価する方法
JP6789420B2 (ja) * 2018-03-29 2020-11-25 三菱電機ビルテクノサービス株式会社 加熱装置、加熱方法、及び冷媒回収方法
WO2019189769A1 (fr) * 2018-03-30 2019-10-03 味の素株式会社 Composition pour croissance cellulaire

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996007427A1 (fr) * 1994-09-02 1996-03-14 Brigham And Women's Hospital, Inc. Immunomodulateur polysaccharidique capsulaire

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3704389A1 (de) * 1987-02-12 1988-08-25 Blutspendedienst Dt Rote Kreuz Verfahren zur herstellung von lymphokinen durch induktion lymphoider zellen
US5858964A (en) * 1995-04-14 1999-01-12 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996007427A1 (fr) * 1994-09-02 1996-03-14 Brigham And Women's Hospital, Inc. Immunomodulateur polysaccharidique capsulaire

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ABSTRACT 98TH MEETING OF AMERICAN SOC FOR MICRO 1998 P 123 *

Also Published As

Publication number Publication date
JP2011121986A (ja) 2011-06-23
JP2002541113A (ja) 2002-12-03
CN1362880A (zh) 2002-08-07
AU4056300A (en) 2000-10-23
CA2366895A1 (fr) 2000-10-12
WO2000059515A9 (fr) 2002-08-29
WO2000059515A3 (fr) 2001-01-11
WO2000059515A2 (fr) 2000-10-12
MXPA01009930A (es) 2003-07-14
EP1169045A2 (fr) 2002-01-09
BR0009531A (pt) 2001-12-26

Similar Documents

Publication Publication Date Title
US20060153832A1 (en) Immunomodulating polymers
JP2011121986A (ja) 免疫調節ポリマー
US5679654A (en) Capsular polysaccharide immunomodulator
EP0778780B1 (fr) Immunomodulateur polysaccharidique capsulaire
Murphy et al. New strategies for preventing graft-versus-host disease
Kim et al. Oral administration of proteoglycan isolated from Phellinus linteus in the prevention and treatment of collagen-induced arthritis in mice
US7629330B2 (en) Use of zwitterionic polysaccharides for the specific modulation of immune processes
Enioutina et al. TLR ligands that stimulate the metabolism of vitamin D3 in activated murine dendritic cells can function as effective mucosal adjuvants to subcutaneously administered vaccines
JP2010265293A (ja) 免疫無防備状態の個体群に用いる糖コンジュゲートワクチン
Prakken et al. Heat shock protein 60 and adjuvant arthritis: a model for T cell regulation in human arthritis
EP0681479B1 (fr) Composition immunotherapeutique
EP1459757A1 (fr) Polymères immunomodulateurs
US7629313B2 (en) Immunomodulatory polymeric antigens for treating inflammatory pathologies
US20090176696A1 (en) Methods And Compositions For Modulating An Immune Response
AU2004280329B2 (en) Synthetic polysaccharide antigens for immunological intervention in disease
AU2005201963B2 (en) Immunomodulating polymers
WO2009139655A2 (fr) Utilisation d’une fraction d’exopolysaccharide produite par lactobacillus rhamnosus
AU702325C (en) Capsular polysaccharide immunomodulator
AU738824B2 (en) Capsular polysaccharide immunomodulator
EP0842666A2 (fr) Utilisation combinée des peptides synthétiques contre l'endotoxine et des anticorps contre l'endotoxine pour la prophylaxie et le traitement de l'endotoxicose et du choc septique